The FDA has rapidly approved infigratinib (Truseltiq, QED Therapeutics) for the treatment of adults with locally advanced or metastatic cholangiocarcinoma who have been previously treated with fibroblast growth factor fusion. strand 2 (FGFR2) or other rearrangement.